Recent Updates
Recently added Catalysts
INO Positive Sentiment Score: 70/100

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

Monday, February 10, 2025 2 min read
Key Takeaway: INOVIO Pharmaceuticals is set to present an abstract on INO-3107 at the upcoming AACR Immuno-Oncology Conference. The poster will detail the loss of detectable HPV-6 in patients with Recurrent Respiratory Papillomatosis following treatment. This presentation highlights the immunological activity of INO-3107, and the abstract will be accessible on INOVIO's website after the event. The conference occurs from February 23-26, 2025, and focuses on innovations in immunotherapy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation of data at a recognized scientific conference
  • Potential advancement in treating HPV-related diseases
  • Induction of emergent T cells shows promise in clinical response

Full Press Release Details

Poster will describe loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following treatment with INO-3107
PLYMOUTH MEETING, Pa., Feb. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that an abstract describing the immunological activity of INO-3107 will be presented as a poster at the following scientific conference:
American Association for Cancer Research – Immuno-Oncology
Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy (February 23-26, 2025)
Poster entitled: "Loss of Detectable HPV-6 Following Induction of Emergent T cells in Patients with Durable Complete Clinical Response to Treatment for Recurrent Respiratory Papillomatosis using INO-3107"
The abstract will be made available on INOVIO's website following the conference.
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Media: Jennie Willson, (267) 429-8567, [email protected]
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505, [email protected]
SOURCE INOVIO Pharmaceuticals, Inc.

21 %

more press release views with

Frequently Asked Questions

What is the focus of INOVIO Pharmaceuticals?

INOVIO specializes in developing DNA medicines for HPV-related diseases, cancer, and infections.

What does the poster presented by INOVIO discuss?

It details the loss of detectable HPV-6 in patients with Recurrent Respiratory Papillomatosis after treatment with INO-3107.

When will the conference on immunotherapy take place?

The conference will occur from February 23-26, 2025.

Where can I find the abstract after the conference?

The abstract will be available on INOVIO's official website after the event.

What is INO-3107 used to treat?

INO-3107 is used to treat Recurrent Respiratory Papillomatosis by inducing T cells.

Tags: INO Viatris Investor Conferences Healthcare INO-3107 HPV immunotherapy AACR-IO Recurrent Respiratory Papillomatosis
Last updated: Feb 10, 2025